Why the study?
Does etanercept therapy improve heart rate variability in young patients with moderate-to-severe psoriasis without cardiovascular risk factors?
Cohort (n=19)
Does etanercept therapy improve heart rate variability in young patients with moderate-to-severe psoriasis without cardiovascular risk factors?
Etanercept therapy for 24 weeks in young patients with moderate-to-severe psoriasis significantly improved heart rate variability markers of sympathetic activity, suggesting a potential reduction in cardiovascular risk.
May indicate autonomic benefits of etanercept in psoriasis; hypothesis-generating and should not yet change practice.
OBJECTIVE: To assess the influence of etanercept, an anti-tumour necrosis factor (TNF)-α agent, on autonomic cardiovascular regulation in young patients with moderate-to-severe psoriasis without cardiovascular risk factors. METHODS: Patients with psoriasis underwent 5-min electrocardiogram (ECG) recordings before and after 24 weeks of etanercept therapy. Linear heart rate variability (HRV) analysis was performed. RESULTS: The study recruited 19 patients. Frequency-domain analysis showed a significant decrease in oscillatory components attributable to sympathetic activity (LF%) and a significant decrease in low frequency/high frequency (LF/HF) ratio following etanercept therapy. CONCLUSION: Treatment with etanercept in patients with moderate-to-severe psoriasis could affect cardiovascular autonomic regulation, and subsequently reduce cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Potenza et al. (2016) conducted a cohort in Moderate-to-severe psoriasis (n=19). Etanercept vs. Baseline (before therapy) was evaluated on Heart rate variability (LF% and LF/HF ratio).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: